Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1. 1992

R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
Advanced BioScience Laboratories, Kensington, Md 20895.

The major neutralizing epitope on the external glycoprotein of HIV-1 was studied with an envelope-specific monoclonal antibody and with a human serum positive for antibodies to HIV-1 proteins, both of which were able to neutralize virus infectivity. The monoclonal antibody reacted specifically with gp120 from HIV-1IIIB, and was shown to neutralize infection of CEM cells by cell-free virions, and inhibited the formation of syncytia normally observed when uninfected cells are cocultured with HIV-1-infected cells. Similar neutralization of viral infection and inhibition of syncytia formation was also demonstrated by the HIV-1-antibody-positive human serum. By examining a number of overlapping peptides from a region of HIV-1 gp120 known to contain a neutralizing epitope, this epitope was localized between amino acids 307 and 320 (V3 loop) in the external glycoprotein molecule. The monoclonal antibody did not interfere with the binding of gp120 to CD4, or with the subsequent step of CD4-induced shedding of gp120 from the viral envelope. However, it blocked the proteolytic cleavage of the V3 loop by thrombin, suggesting that the antibody may be inhibiting the interaction of the loop with other membrane-bound proteins.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
June 1988, AIDS research and human retroviruses,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
April 1995, AIDS research and human retroviruses,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
February 1988, AIDS (London, England),
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
September 1993, Disease markers,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
January 1994, Human antibodies and hybridomas,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
October 1995, Molecular immunology,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
December 2023, bioRxiv : the preprint server for biology,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
April 1995, AIDS research and human retroviruses,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
January 1991, Journal of clinical laboratory analysis,
R Pal, and F di Marzo Veronese, and B C Nair, and R Rahman, and G Hoke, and S W Mumbauer, and M G Sarngadharan
May 1992, Infection and immunity,
Copied contents to your clipboard!